Notice of Two Year Exclusivity Period; DAYPRORegister Oxaprozin
The Patent and Trademark Office has received notification from G. D. Searle & Co. that it claims entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134) for its drug product DAYPRO oxaprozin.
- Task
- Read the news
- Patent or trademark
- both
- Legacy system
- —
- Current entry point
- www.federalregister.gov/documents/1996/05/22/96-12882/notice-of-two-year-exclusivity-period-dayproregister-oxaprozin (permanent link in the Federal Register, verified 2026-09-30)
- Legacy system and where it moved
- No legacy system name mention in title or summary )
- Fee
- No fee mention in title or summary )
- What you need (account or API key)
- No account or key mention in title or summary )
- Published
- 1996-05-22
- Document type
- Notice
- Source
- USPTO documents published in the Federal Register (Federal Register API)(retrieved 2026-10-06)
Everything in the same category
Read the news (all 1988) · both (all 2333)
Related entry points
- Extension of the Period for Comments on the Enhancement of Quality of Software-Related Patents
- Grant of Certificate of Interim Extension of the Term of U.S. Patent No. 4,048,306; Dynabac
- Fast-Track Pilot Program for Appeals Related to COVID-19
- Grant of Certificate of Interim Extension of the Term of U.S. Patent No. 4,066,772; Motilium
- Grant of Certificate of Interim Extension of the Term of U.S. Patent No. 4,062,848; Remeron
- Grant of Certificate of Interim Extension of the Term of U.S. Patent No. 4,197,297; CORLOPAMRegister
- Changes To Permit Delayed Submission of Certain Requirements for Prioritized Examination
- Request for Comments on Proposed Change To Missing Parts Practice
- Request for Comments on Interim Guidelines for Examination of Patent Applications for Patent Subject Matter Eligibility
- Treatment of Letters Stating That the USPTO's Patent Term Adjustment Determination Is Greater Than What the Applicant or Patentee Believes Is Appropriate
- Deferred-Fee Provisional Patent Application Pilot Program and Collaboration Database To Encourage Inventions Related To COVID-19
- Request for Comments on Preparation of Patent Applications
- Changes To Practice for Continuing Applications, Requests for Continued Examination Practice, and Applications Containing Patentably Indistinct Claims
- Notice Regarding Options for Amendments by Patent Owner Through Reissue or Reexamination During a Pending AIA Trial Proceeding (April 2019)
- Revision of Patent and Trademark Fees for Fiscal Year 1998
- Changes To Implement the Prioritized Examination Track (Track I) of the Enhanced Examination Timing Control Procedures